Journey Medical Corp DERM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DERM is a good fit for your portfolio.
News
-
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
-
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
-
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
-
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
-
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
-
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference
-
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting
-
Journey Medical Stock Falls 21% on Plans for Rosacea FDA New Drug Application
Trading Information
- Previous Close Price
- $3.63
- Day Range
- $3.52–3.73
- 52-Week Range
- $1.02–8.11
- Bid/Ask
- $3.40 / $4.75
- Market Cap
- $73.55 Mil
- Volume/Avg
- 51,784 / 154,240
Key Statistics
- Price/Earnings (Normalized)
- 179.26
- Price/Sales
- 0.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 58
Valuation
|
Metric
|
DERM
|
|---|---|
Price/Earnings (Normalized) | 179.26 |
Price/Book Value | 3.50 |
Price/Sales | 0.85 |
Price/Cash Flow | 9.76 |
Price/Earnings
DERM
Financial Strength
|
Metric
|
DERM
|
|---|---|
Quick Ratio | 1.02 |
Current Ratio | 1.35 |
Interest Coverage | −1.33 |
Quick Ratio
DERM
Profitability
|
Metric
|
DERM
|
|---|---|
Return on Assets (Normalized) | 1.25% |
Return on Equity (Normalized) | 8.30% |
Return on Invested Capital (Normalized) | 7.96% |
Return on Assets
DERM
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Twsvwjkmzg | Rhp | $76.2 Bil | |
MKKGY
| Merck KGaA ADR | Mwbgyqlmk | Rlyfv | $70.9 Bil | |
HLN
| Haleon PLC ADR | Gqqkbqj | Mxs | $37.8 Bil | |
VTRS
| Viatris Inc | Rxlhthw | Ghq | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Rnjcybmdp | Vlyzl | $12.7 Bil | |
CTLT
| Catalent Inc | Zsyppfcps | Tgbjv | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Fchsxnwvy | Chyz | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Gkbsfxhy | Znwdt | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Dqqzvkmk | Dxkbcc | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Dzccffcwh | Jbz | $3.1 Bil |